肺癌筛检市场规模、份额和成长分析（按癌症类型、诊断类型、最终用户和地区）- 产业预测 2025-2032

2023 年全球肺癌筛检市场规模价值为 35 亿美元，预计将从 2024 年的 38.2 亿美元成长到 2032 年的 76.6 亿美元，预测期间（2025-2032 年）的复合年增长率为 9.1%。

受筛检技术进步和烟草使用率上升的推动，全球肺癌筛检市场预计将经历显着成长。据报道，2021 年约有 255 万名学生消费烟草製品，截至 2020 年，美国约有 13% 的成年人吸烟，肺癌发病率的增加推动了对有效筛检解决方案的需求。低剂量电脑断层扫描（CT）在医疗保健专业人士中越来越受欢迎，尤其是在印度和中国等开发中国家，人们对这种创新筛检技术的认识日益加深。合作努力也正在出现，例如合作宣传计划。然而，筛检的高成本和对辐射暴露的担忧是显着的挑战。透过技术进步和公众教育解决这些问题对于市场持续成长至关重要。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 技术进步
• 监管格局
• 专利分析

肺癌筛检市场规模（按癌症类型和复合年增长率） (2025-2032)

• 市场概况
• 非小细胞肺癌（NSCLC）
• 小细胞肺癌

肺癌筛检市场规模（依诊断类型和复合年增长率）（2025-2032）

• 市场概况
• 低剂量螺旋电脑断层扫描
• 胸部 X 光检查

肺癌筛检市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院和诊所
• 诊断中心

肺癌筛检市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• General Electric Company（USA）
• Koninklijke Philips NV（Netherlands）
• Siemens Healthineers（Germany）
• Canon Medical Systems Corporation（Japan）
• FUJIFILM Holdings Corporation（Japan）
• Medtronic（USA）
• Nuance Communications, Inc.（USA）
• Eon（USA）
• Volpara Health Limited（New Zealand）
• Hitachi, Ltd.（Japan）
• Toshiba Corporation（Japan）
• Hologic, Inc.（USA）
• Agfa-Gevaert Group（Belgium）
• Carestream Health（USA）
• Mindray Medical International Limited（China）
• Esaote SpA（Italy）
• Shimadzu Corporation（Japan）
• ViewRay, Inc.（USA）

结论和建议

Global Lung Cancer Screening Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 3.82 billion in 2024 to USD 7.66 billion by 2032, growing at a CAGR of 9.1% during the forecast period (2025-2032).

The global lung cancer screening market is poised for significant growth, fueled by advancements in screening technologies and the rising prevalence of tobacco use. With approximately 2.55 million students reportedly consuming tobacco products in 2021 and nearly 13% of U.S. adults smoking cigarettes as of 2020, the increasing incidence of lung cancer heightens the demand for effective screening solutions. Low-dose computed tomography (CT) is gaining traction among healthcare professionals, particularly in developing countries like India and China, where awareness of innovative screening techniques is on the rise. Collaborative initiatives, such as partnerships for awareness programs, have also emerged. However, high screening costs and concerns about radiation exposure present notable challenges. Addressing these issues through technological advancements and public education will be vital for sustained market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Screening Market Segments Analysis

Global Lung Cancer Screening Market is segmented by Cancer Type, Diagnosis Type, End-user and region. Based on Cancer Type, the market is segmented into Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer. Based on Diagnosis Type, the market is segmented into Low Dose Spiral CT Scan and Chest X-ray. Based on End-user, the market is segmented into Hospitals & Clinics and Diagnostic Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lung Cancer Screening Market

The Global Lung Cancer Screening market is significantly propelled by the alarming rise in lung cancer cases, which continues to be one of the foremost causes of cancer-related fatalities across the globe. This increasing prevalence, particularly in developing nations, highlights an urgent need for effective early detection methods. Consequently, there is a growing impetus for the implementation of screening programs aimed at identifying lung cancer at its initial stages. As awareness of lung cancer's impact rises, healthcare systems are increasingly prioritizing screening initiatives, thereby fostering the expansion and development of the lung cancer screening market on a global scale.

Restraints in the Global Lung Cancer Screening Market

The Global Lung Cancer Screening market faces several challenges, particularly associated with the use of Low-Dose Computed Tomography (LDCT) screenings. These screenings can sometimes yield false-positive results, necessitating further tests and creating unwarranted anxiety for patients. Additionally, these unnecessary investigations can incur extra costs and may even expose patients to complications arising from unnecessary procedures. Another concern is the issue of overdiagnosis, where patients are identified with lung nodules that are unlikely to cause harm. This situation can result in overtreatment and invasive interventions, complicating the overall management of patients and negatively impacting their quality of life.

Market Trends of the Global Lung Cancer Screening Market

The Global Lung Cancer Screening market is increasingly moving towards personalized screening approaches, reflecting a significant trend characterized by the customization of screening strategies based on individual risk factors such as smoking history, occupational exposures, and genetic predispositions. By implementing risk stratification algorithms, healthcare providers can identify high-risk populations more effectively, thereby optimizing resource allocation and enhancing the overall efficacy of screening interventions. This shift not only improves early detection rates but also aligns with the broader healthcare movement towards precision medicine, ultimately driving market growth as stakeholders invest in technologies and solutions that cater to diverse patient profiles and enhance healthcare outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Advancement
• Regulatory Landscape
• Patent Analysis

Global Lung Cancer Screening Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer

Global Lung Cancer Screening Market Size by Diagnosis Type & CAGR (2025-2032)

• Market Overview
• Low Dose Spiral CT Scan
• Chest X-ray

Global Lung Cancer Screening Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers

Global Lung Cancer Screening Market Size & CAGR (2025-2032)

• North America (Cancer Type, Diagnosis Type, End-user)
  • US
  • Canada
• Europe (Cancer Type, Diagnosis Type, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Diagnosis Type, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Diagnosis Type, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Diagnosis Type, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• General Electric Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Medical Systems Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nuance Communications, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eon (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Volpara Health Limited (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hitachi, Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Toshiba Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agfa-Gevaert Group (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carestream Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mindray Medical International Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Esaote S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shimadzu Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViewRay, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations